EUVIMEDEUVIMED entdecken
Crossref

Single Centre Experience: Bening and Malign Hematological Patients with COVID-19

Pınar TIĞLIOĞLU, Murat ALBAYRAK, Hacer Berna AFACAN ÖZTÜRK, Mesut TIĞLIOĞLU, Buğra SAĞLAM, Merih REİS ARAS, Fatma YILMAZ, Senem MARAL, Ümit Yavuz MALKAN

Sağlık Akademisi Kastamonu · 2022

DOI: 10.25279/sak.1061701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sağlık Akademisi Kastamonu, 2022. Verfasst von Pınar TIĞLIOĞLU und 8 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Coronavirus disease 2019 (COVID-19) were declared as pandemic by World Health Organization. With this study, we aimed to define our patients who were followed up with malign or benign hematological diagnoses and diagnosed with COVID-19; determine the distribution of this infection in patient groups and contribute to the literature by creating descriptive statistics with its clinical and demographic features. Patients and methods: It is planned to retrospectively examine patients with a history of COVID-19 who were followed up in Hematology Department of Dışkapı Yıldırım Beyazıt Training and Research Hospital with benign and malignant diagnoses.

Results

88 patients who had COVID-19 infection while being followed in our clinic due to hematological diseases were included in the study. 77 patients had been followed by hematologic malignancies and 11 patients had been followed by benign hematological disease.In the group with malignancy, COVID was found most frequently in patients diagnosed with Philadelphia chromosome negative myeloproliferative neoplasms (22%), nonhodgkin lymphoma (19%) and multiple myeloma (16%). ITP (64%) was the most common disease in patients with benign hematological disorder who had COVID history. 52 (67%) of the malignant cases and 8 (73%) of the bening cases were found to be followed up with the disease in remission. The all patient's most common symptoms at COVID-19 diagnosis were fever (77%), cough (70%) and weakness (65%). 45% of the patients were isolated at home, 48% were required hospitalization. 49% of patients had mild; 27% had moderate and 24% had severe COVID-19 infection. Almost all of the patients in the moderate and severe disease group were followed up in patients diagnosed with malignant hematological disease. 16 (18%) patients received mechanical ventilation and 16 (18%) patients was transferred intensive care unit. All of the patients who were intubated and needed intensive care were diagnosed with malignant hematological disease. 17 patients died due to COVID-19 infection. The mortality rate was 22% in patients with diagnosis of malignant hematological diseases, and 19% when all patients (malignant and bening) were included.

Conclusion

In conclusion, the COVID-19 pandemic is a problem all over the world. Determining the course of the disease in certain diagnostic groups is important in the management of both the main disease and the COVID-19 infection. Therefore, the contribution of such recording studies to the literature is important and valuable.

Zitieren

APA

TIĞLIOĞLU, P., ALBAYRAK, M., ÖZTÜRK, H. B. A., TIĞLIOĞLU, M., SAĞLAM, B., ARAS, M. R., YILMAZ, F., MARAL, S., & MALKAN, Ü. Y. (2022). Single Centre Experience: Bening and Malign Hematological Patients with COVID-19. Sağlık Akademisi Kastamonu. https://doi.org/10.25279/sak.1061701

Vancouver

TIĞLIOĞLU P, ALBAYRAK M, ÖZTÜRK HBA, TIĞLIOĞLU M, SAĞLAM B, ARAS MR, et al. Single Centre Experience: Bening and Malign Hematological Patients with COVID-19. Sağlık Akademisi Kastamonu. 2022. doi:10.25279/sak.1061701

BibTeX
@article{TILIOLU2022,
  author = {TIĞLIOĞLU, Pınar and ALBAYRAK, Murat and ÖZTÜRK, Hacer Berna AFACAN and TIĞLIOĞLU, Mesut and SAĞLAM, Buğra and ARAS, Merih REİS and YILMAZ, Fatma and MARAL, Senem and MALKAN, Ümit Yavuz},
  title = {Single Centre Experience: Bening and Malign Hematological Patients with COVID-19},
  journal = {Sağlık Akademisi Kastamonu},
  year = {2022},
  doi = {10.25279/sak.1061701}
}
Kostenlos starten →